Increased Expression of Tumor Proliferation Genes in Hispanic Women with Early-Stage Breast Cancer

Hispanic women have higher breast cancer mortality compared to non-Hispanic whites. We evaluated for Proliferation Axis Score differences, as determined by Oncotype Dx, in Hispanic and non-Hispanic white women with newly diagnosed breast cancer. We matched 219 women, based upon age, stage, and nodal status. Compared to non-Hispanic whites, Hispanic women with hormone-sensitive, HER2-negative early-stage breast cancer had a higher Proliferation Axis Score. No differences were seen in Recurrence Score, ER, PR, or HER2 by Oncotype DX. CCNB1 and AURKA were significantly higher in Hispanic women. These tumor differences may help explain breast cancer outcome differences between the two ethnicities.

[1]  Mutsuko Ouchi,et al.  BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. , 2015, The Journal of Biological Chemistry.

[2]  P. Porter,et al.  Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population , 2012, Cancer Causes & Control.

[3]  E. Perez,et al.  Obesity at diagnosis is associated with inferior outcomes in hormone receptor‐positive operable breast cancer , 2012, Cancer.

[4]  J. Rahnenführer,et al.  Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients , 2012, BMC Cancer.

[5]  H. Selby,et al.  Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models , 2012, Clinical Cancer Research.

[6]  Deepa Naishadham,et al.  Cancer statistics for Hispanics/Latinos, 2012 , 2012, CA: a cancer journal for clinicians.

[7]  Stephen C. Peiper,et al.  Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells , 2012, Breast Cancer Research and Treatment.

[8]  Charles M. Perou,et al.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.

[9]  L. Butler,et al.  Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors , 2012, Cell cycle.

[10]  W. Miller,et al.  Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score , 2011, British Journal of Cancer.

[11]  C. Cohen,et al.  Proliferation (Ki-67 and Phosphohistone H3) and Oncotype DX Recurrence Score in Estrogen Receptor-positive Breast Cancer , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[12]  S. Ooi,et al.  Disparities in breast cancer characteristics and outcomes by race/ethnicity , 2011, Breast Cancer Research and Treatment.

[13]  M. Hammond,et al.  Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Coory,et al.  Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis , 2010, Breast Cancer Research and Treatment.

[15]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[16]  G. Hortobagyi,et al.  Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer. , 2010 .

[17]  M. Piccart-Gebhart,et al.  Value of Ki67 in breast cancer: the debate is still open. , 2010, The Lancet. Oncology.

[18]  Jack Cuzick,et al.  Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Pustilnik,et al.  PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy , 2010, Molecular Cancer Therapeutics.

[20]  K. Gelmon,et al.  Ki67 in breast cancer: prognostic and predictive potential. , 2010, The Lancet. Oncology.

[21]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Michael M. Engelgau,et al.  Prevalence of Diabetes and Impaired Fasting Glucose in Adults in the U.S. Population , 2006, Diabetes Care.

[23]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[24]  K. Malone,et al.  Differences in breast cancer stage, treatment, and survival by race and ethnicity. , 2003, Archives of internal medicine.

[25]  P. Porter,et al.  Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma , 2001, Cancer.

[26]  G. Bevilacqua,et al.  Cyclins of phases G1, S and G2/M are overexpressed in aneuploid mammary carcinomas. , 2000, Cytometry.

[27]  F. Gilliland,et al.  Breast cancer survival among New Mexico Hispanic, American Indian, and non-Hispanic white women (1973-1992). , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  P. Tartter,et al.  Ethnic differences in risk and prognostic factors for breast cancer , 1995, Cancer.

[29]  G M Clark,et al.  Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. , 1994, Journal of the National Cancer Institute.

[30]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[31]  Robert B Livingston,et al.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. , 2010, The Lancet. Oncology.

[32]  M. Beydoun,et al.  The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. , 2007, Epidemiologic reviews.